| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Didesmethylsibutramine hydrochloride targets NMDA receptors by inhibiting NMDA-evoked activity. It also inhibits the reuptake of neurotransmitters. It induces thermogenesis. As a metabolite of sibutramine, it contributes to the pharmacological effects of the parent drug.
|
|---|---|
| ln Vitro |
In vitro, didesmethylsibutramine hydrochloride inhibits NMDA-evoked activity. It is a reuptake inhibitor. It is studied for its potential applications in the treatment of central nervous system disorders and obesity.
|
| ln Vivo |
In vivo, didesmethylsibutramine hydrochloride is the primary amine metabolite of sibutramine. It induces thermogenesis. It is a major pharmacologically active metabolite that contributes to the anti-obesity and antidepressant effects of sibutramine.
|
| Enzyme Assay |
In vitro assays for didesmethylsibutramine hydrochloride typically involve studying its effects on neurotransmitter reuptake and NMDA receptor activity. NMDA-evoked activity is measured in neuronal cell preparations. Neurotransmitter reuptake inhibition is assessed using synaptosomal preparations or cell lines expressing neurotransmitter transporters.
|
| Cell Assay |
For in vitro cell assays, cells expressing NMDA receptors or neurotransmitter transporters are cultured and treated with didesmethylsibutramine hydrochloride at various concentrations. NMDA-evoked currents or calcium influx are measured. Neurotransmitter uptake inhibition is quantified using radiolabeled substrates. Cell viability is assessed by MTT assay.
|
| Animal Protocol |
For in vivo animal studies, didesmethylsibutramine hydrochloride is typically studied as a metabolite of sibutramine. Animals are administered sibutramine, and blood and tissue samples are collected. The compound is quantified by LC-MS. Its effects on thermogenesis, appetite, and neurotransmitter levels are assessed.
|
| ADME/Pharmacokinetics |
Didesmethylsibutramine hydrochloride (BTS 54-505) has the molecular formula C₁₂H₁₉ClN₂. It is a hydrochloride salt form of the primary amine metabolite of sibutramine. The compound is stable under recommended storage conditions. It is soluble in water and organic solvents.
|
| Toxicity/Toxicokinetics |
The compound is for research use only. No specific toxicity data are available. As a metabolite of sibutramine, its toxicity profile is expected to be related to the parent drug. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
[1]. Liu YL, et al. Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine. Int J Obes Relat Metab Disord. 2002 Sep;26(9):1245-53.
[2]. Scott G, et al. The effects of BTS 54,505, a metabolite of sibutramine, on monoamine and excitatory amino acid-evoked responses in the rat dorsolateral geniculate nucleus in vivo. Br J Pharmacol. 1994 Jan;111(1):97-102. |
| Additional Infomation |
Didesmethylsibutramine hydrochloride (CAS# 84484-78-6) is the primary amine metabolite of the anti-obesity agent sibutramine. It has not been approved as a therapeutic agent. The compound is used in research on obesity, central nervous system disorders, and neurotransmitter reuptake inhibition. It is also known as BTS 54-505.
|
| Molecular Formula |
C15H23CL2N
|
|---|---|
| Molecular Weight |
288.26
|
| Exact Mass |
287.12
|
| CAS # |
84484-78-6
|
| Related CAS # |
Didesmethylsibutramine-d7 hydrochloride;1188263-87-7
|
| PubChem CID |
134771
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
337.9ºC at 760 mmHg
|
| Melting Point |
160 - 166°C (lit.)
|
| Flash Point |
195.1ºC
|
| LogP |
5.637
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
239
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl.ClC1C=CC(C2(CCC2)C(CC(C)C)N)=CC=1
|
| InChi Key |
KHRVYINTXCWNRF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H22ClN.ClH/c1-11(2)10-14(17)15(8-3-9-15)12-4-6-13(16)7-5-12;/h4-7,11,14H,3,8-10,17H2,1-2H3;1H
|
| Chemical Name |
1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4691 mL | 17.3455 mL | 34.6909 mL | |
| 5 mM | 0.6938 mL | 3.4691 mL | 6.9382 mL | |
| 10 mM | 0.3469 mL | 1.7345 mL | 3.4691 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
